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Abstract 
The development of bacteria-specific infection radiotracers is of considerable interest to 
improve diagnostic accuracy and enabling therapy monitoring. The aim of this study was to 
determine if the previously reported radiolabelled 1,4,7,10-tetraazacyclododecane-
N,N′,N″,N‴-tetraacetic acid (DOTA) conjugated peptide, [
68
Ga]Ga-DOTA-K-A9 could detect 
a staphylococcal infection in vivo, and distinguish it from aseptic inflammation. An optimised 
[
68
Ga]Ga-DOTA-K-A9 synthesis omitting the use of acetone was developed, yielding 93% ± 
0.9% radiochemical purity. The in vivo infection binding specificity of [
68
Ga]Ga-DOTA-K-
A9 was evaluated by micro positron emission tomography/magnetic resonance imaging 
(µPET/MRI) of 15 mice with either subcutaneous S. aureus infection or turpentine induced 




F]FDG). The scans 
showed that [
68
Ga]Ga-DOTA-K-A9 accumulated in all the infected mice at injected doses 
≥3.6 MBq. However, the tracer was not found to be selective towards infection, since the 
[
68
Ga]Ga-DOTA-K-A9 also accumulated in mice with inflammation.  
In a concurrent in vitro binding evaluation performed with a 5-Carboxytetramethylrhodamine 
(TAMRA) fluorescence analogue of the peptide, TAMRA-K-A9, the microscopy results 
suggested that TAMRA-K-A9 bound to an intracellular epitope and therefore preferentially 
targeted dead bacteria. Thus, the [
68
Ga]Ga-DOTA-K-A9 uptake observed  in vivo is 
presumably a combination of local hyperaemia, vascular leakiness and/or binding to an 
epitope present in dead bacteria.   
 
Keywords: PET, gallium-68, [
68
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1 Introduction 
Timely and accurate diagnosis of bacterial infections is essential for successful patient 
treatment. In addition to conventional analyses of blood, urine, or tissue biopsy, diagnosis is 
often made with non-invasive imaging modalities i.e. anatomical or functional.
1-3
 However, 
with anatomical imaging techniques, such as magnetic resonance imaging (MRI) and 
computed tomography (CT), an infection only becomes apparent when the lesion has resulted 
in anatomical changes. Thus, CT and MRI are frequently applied in combination with the 
functional imaging technique of positron emission tomography (PET) that allows detection of 
early pathophysiologic changes prior to anatomical alterations. A general shortcoming of the 





F]FDG), are their inability to distinguish between different sources of 
inflammation, i.e. between sterile inflammation, infection or malignancy.
4,5
  
The development of bacteria-specific radiotracers for infection is therefore of considerable 
interest to improve diagnostic accuracy and thereby patient treatment. The field of developing 
bacteria-specific radiotracers, targeting unique bacterial characteristics, has been explored 
during the past decades;
1,3,6
 among the most extensively researched tracers are the 
radiolabelled antibiotic ciprofloxacin and the antimicrobial peptide ubiquicidin.
7-13
 Recently, 





maltohexaose, have exploited the differences in sugar metabolism of bacteria and human 
cells with promising results.
14,15
 In most cases, however, it is unknown if or to what extent 




S. aureus is a major cause of soft tissue, endovascular, bone and post-surgical infections, and 
is often associated with abscess and biofilm formation.
16,17
 We have earlier reported the 
identification of the dodecapeptide A9 by phage-display selection against S. aureus biofilm, 
 
This article is protected by copyright. All rights reserved. 
as well as the gallium-68 labelling, and initial biological evaluation of the 1,4,7,10-
tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) conjugated peptide DOTA-K-A9 
(FigureA) as a potentially bacteria-specific PET-tracer.
18
 
The purpose of this study was to further investigate if the [
68
Ga]Ga-DOTA-K-A9 was able to 
differentiate between infected and aseptic inflamed tissues using µPET/MRI and compare it 
to [
18
F]FDG in murine subcutaneous (SC) infection and inflammation models. A parallel in 
vitro binding evaluation of the 5-Carboxytetramethylrhodamine (TAMRA) fluorescence 
analogue, TAMRA-K-A9 (FigureB), was performed with different viable and dead bacterial 
cultures to further characterise the bacterial binding of the A9 peptide.   
 
2 Experimental  
2.1 Materials  
All chemicals were of analytical grade or better and used without further purification. The 
main suppliers were Sigma-Aldrich (Brøndby, Denmark) and Merck (Darmstadt, Germany). 
Aqueous solutions for high performance liquid chromatography (HPLC) analysis were 
prepared with deionised distilled water (Milli-Q water system; Millipore, Aarhus, Denmark). 
In all other aqueous solutions water for injection (Danish Capital Region Pharmacy) was 
applied. The DOTA-K-A9 peptide for gallium-68 labelling and the fluorescence analogue of 
the peptide TAMRA-K-A9 were custom synthesised by Pepscan (Lelystad, The Netherlands). 
The membrane-impermeable DNA-binding stain TOTO®-1 was bought from Thermo Fisher 
(Nærum, Denmark). [
68
Ga]GaCl3 for radiolabelling was obtained from an IGG100-50M 
gallium-68 generator commercially available from Eckert & Ziegler (Berlin, Germany), 
yielding in the range of 0.6 - 1.0 GBq.  
Cationic exchange cartridges Varian SCX (50 µg, 1 ml) were from Agilent Technologies 
(Glostrup, Denmark). Sep-Pak (55-105 µm particles) C18-light (130 mg) cartridges were 
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obtained from Waters (Hedehusene, Denmark). The gallium-68 labelling was performed with 
reused, commercially available cassettes, which were washed and applied with new 
cartridges.  
Radiosyntheses were done on an automated ModularLab PharmTracer synthesis module from 
Eckert & Ziegler (Berlin, Germany) employing a self-designed synthesis program 
19
. Purity 
analyses of the radiolabelled compounds were performed using reversed-phase HPLC on an 
Ultimate 3000 system from Dionex (Hvidovre, Denmark) and thin-layer chromatography 
(TLC) on a PET miniGita* TLC scanner from Raytest (Straubenhardt, Germany). The 
acetone and ethanol content in the product was analysed by Gas Chromatography (GC) on a 
Clarus 480 GC from Perkin Elmer (Skovlunde, Denmark), pH-values were measured 
applying a PH M220 pH-meter from Radiometer Analytical (Villeurbanne, France), and the 
radioactivity of the products was determined by a VDC-405 dose calibrator from Veenstra 
Instruments (Joure, The Netherlands). 
The binding selectivity of [
68
Ga]Ga-DOTA-K-A9 was evaluated by µPET/MRI on mice 
using an integrated Mediso NanoScan® PET/MRI system from Mediso Medical Imaging 
Systems (Budapest, Hungary). 
 
2.2 Bacteria  
The different bacteria used in the study are listed in Table 1. The S. aureus isolate originating 
from a clinical prosthesis infection, which was used to prepare the biofilm applied in the 
preceding phage-display selection of the A9 peptide,
18
 was also used in both the murine SC 
infection model and in vitro evaluation of TAMRA-K-A9. The bacteria were grown 
overnight from a single colony in tryptic soy broth (TSB) at 37 °C while being gently shaken 
at 200 rpm on an incubator shaker (IKA KS 4000i control, from VWR). Following overnight 
incubation, the bacteria suspension was density adjusted according to 600 nm absorbance 
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with TSB (5x 10
7
 colony forming unit (CFU)/ml) for the mice inoculation. For the 
morphological in vitro evaluation, samples of dead bacteria were additionally prepared by 
immersing a swap in each of the fresh bacteria cultures and subsequently transferring the 
swaps with bacteria to tubes containing CyMol® (COPAN, Italy) and incubated for 10 min at 
room temperature, to kill the bacteria. Then the tubes were vortexed shortly, before the 
solutions (1 ml each) were transferred to new tubes. 
 
2.3 Radiochemistry 
2.3.1 Initial gallium-68 labelling of DOTA-K-A9   
The [
68
Ga]Ga-DOTA-K-A9 for the mice pilot infection study was prepared as previously 
described.
18
 Briefly, approx. 1.0 GBq [
68
Ga]GaCl3 was eluted from the generator with 0.1 M 
HCl (10 ml) and trapped on a Strata-X-C cartridge, before it was eluted with a 0.02 M HCl/ 
acetone (97.6%) solution (600 µl). The [
68
Ga]Ga-DOTA-K-A9 was synthesised by dissolving 
DOTA-K-A9 (66 µg, 35 nmol) in 0.1 M 2-[4-(2-hydroxyethyl)piperazin-1-yl]-ethanesulfonic 
acid (HEPES) aq. solution (5 ml) pH 4, adjusted with 30% HCl, added pre-purified 
[
68
Ga]GaCl3 (600 µl) and heated at 95 °C for 5 min. The [
68
Ga]Ga-DOTA-K-A9 formulation 
(pH 3.9 - 4.1) was used without further purification, but diluted with saline to obtain an 
acetone content <4000 ppm in the in vivo injections. 
 
2.3.2 Optimized gallium-68 labelling of DOTA-K-A9   
In the optimised production of [
68
Ga]Ga-DOTA-K-A9, which was applied in the mice 
infection and inflammation comparison study, approx. 0.6 GBq [
68
Ga]GaCl3 from the 
generator was trapped on a Varian SCX cartridge and eluted with a 5 M NaCl/ 5.5 M HCl 
(2.5%) solution (700 µl).
20
 The following gallium-68 labelling was achieved by mixing the 
pre-purified [
68
Ga]GaCl3 with the precursor DOTA-K-A9 (70 µg, 37 nmol) in 0.1 M HEPES 
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aq. solution pH 6.5 (5 ml) and heated at 95 °C for 3.5 min. The purification of [
68
Ga]Ga-
DOTA-K-A9 was performed using a C18-light cartridge, pre-conditioned with 50% EtOH aq. 
solution (5 ml) and 0.1 M HEPES aq. solution pH 5.2 (5 ml). The pre-conditioning of the 
C18-light cartridge was performed by the automated synthesis module during the 3.5 min 
labelling of the peptide in the reactor. First, the 50% EtOH aq. solution (5 ml) was passed 
through the C18-light cartridge followed by air (10 ml); second, the cartridge was washed 
with the 0.1 M HEPES aq. solution (5 ml) and dried again with air (10 ml). 
After the 3.5 min labelling reaction, the [
68
Ga]Ga-DOTA-K-A9 reaction mixture was 
immediately transferred and trapped on the C18-light cartridge and rinsed with 0.1 M HEPES 
aq. solution pH 5.2 (2 ml), before it was eluted with 50% EtOH aq. solution (1 ml). The final 
formulation (9 ml) of the product was achieved by adding isotonic saline (8 ml). The stability 
of the [
68
Ga]Ga-DOTA-K-A9 in the product formulation (pH 5.1 - 5.7) was evaluated up to 
120 min employing the radio-HPLC setup described in the next section. The product 
formulation was further diluted prior to the biological testing in mice, to achieve an ethanol 
content <5 % (v/v).  
 
2.3.3 Quality control 
Decay corrected radiochemical yield, and radiochemical purity were determined using radio-
TLC and radio-HPLC. The radio-TLC analysis applied silica iTLC sheets from Agilent 
technologies as the stationary phase, and two different mobile phases. Mobile phase I, 0.1 M 
sodium citrate pH 5.5 with the following retention factors (Rf): 0.12 ± 0.03 for [
68
Ga]Ga-
DOTA-K-A9 and 0.85 ± 0.07 for free gallium-68 ions binding to the citrate. Mobile phase II, 
50% 1 M ammonium acetate in methanol with the corresponding Rf: 0.72 ± 0.14 for 
[
68
Ga]Ga-DOTA-K-A9 and 0.02 ± 0.02 for gallium-68 colloid.   
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The analytical HPLC of [
68
Ga]Ga-DOTA-K-A9 was performed using an Aeris Peptide XB-
C18 column (2.6 µm, 150x4.6 mm) from Phenomenex. Here, a binary gradient system with a 
1.0 ml/min flow rate employing 0.1% trifluoroacetic acid (TFA) in water (A) and 0.1% TFA 
in acetonitrile (B) as mobile phases was applied. The mobile phase gradient was as following: 
0-10 min, linear gradient 9.5 to 15% of B; from 10-12 min, linear gradient from 15 to 70% B; 
2 min at 70% B; 2 min decrease in B to 9.5%; 16-20 min at 9.5% B. The compounds were 
eluted: [
68
Ga]GaCl3 at 1.7 ± 0.1 min, DOTA-K-A9 at 6.6 ± 0.2 min, [
68
Ga]Ga-DOTA-K-A9 
7.1 ± 0.5 min. 
 
 
2.4 In vivo evaluation   
2.4.1 Animals  
The studies in mice were performed according to the Danish Animal Experimentation Act 
and the European Convention for the protection of vertebrate animals used for experimental 
and other scientific purposes (ETS No. 123) and the European Union directive on the 
protection of animals used for scientific purposes (2010/63/EU). The Danish Animal 
Experiments Inspectorate granted the animal experiment license (2015-15-0201-00631).  
In this study, C57Bl6/J mice (n = 17, adult, females, 20-22 g) were applied, with the analyses 
performed on each mouse shown in Table 2. The mice for the pilot infection study (n = 3) 
were purchased from M&B Taconic, while the mice in the main infection and inflammation 
comparison study came from Janvier Labs. All animals had an acclimatisation period of 
minimum 7 days at the experimental animal facility. They were housed with a 12 h light/dark 
cycle and had access to tap water ad libitum and pellet feed.  
During the scans the animals were placed on a gantry which regulated the temperature to 37 
°C and they were kept lightly anesthetised by isoflourane in an oxygene-medical air mixture 
 
This article is protected by copyright. All rights reserved. 
through a mask, while they were removed from anaesthesia between scans. After the last PET 
scan, the mice were euthanised by cervical dislocation while still anaesthetised. No blood 
samples were taken during the µPET/MRI experiment.  
 
2.4.2 Murine infection and inflammation models 
The mice were anaesthetised with isofluorane inhalation and pre-operative intra muscular 
injection of buprenorphine (Temgesic, 30 µg/ml, 100 µl). A skin area of approx. 1.5 cm
2
 
above right scapula was shaved and washed with 70% ethanol. After the ethanol had 
evaporated, either S. aureus in TSB suspension (5x 10
7
 CFU/ml, 100 µl) or turpentine (100%, 
100 µl) was injected SC. The hypodermic needle was kept in situ for 5 sec post-injection to 
prevent retrograde leakage of bacterial suspension. Animals were returned to their cages until 
the µPET/MRI-scan were conducted 27 ± 2 h later. Humane endpoints were defined as 
systemic illness, impaired mobility, treatment refractory pain or acute weight loss >15%. 
Post-inoculated, the mice in the comparison study had access to buprenorphine 6.0 µg/ml 
through the drinking water.  
 
2.4.3 µPET/ MRI imaging  
In the pilot study, three anesthetised mice with SC infection underwent a 100 min whole body 
dynamic PET scan immediately after intravenous injection of 3.2 ± 1.5 MBq [
68
Ga]Ga-
DOTA-K-A9, through the tail vein (200-300 µl). A 15 min T2 weighted MRI sequence was 
subsequently acquired for anatomical localisation. Five hours later, allowing for decay of the 
[
68
Ga]Ga-DOTA-K-A9, a 100 min dynamic PET scan was performed 60 min post-injection 




(100-200 µl) followed again by a 15 min MRI scan.  
A similar setup, as described above, was applied in the SC infection and inflammation 
comparison study, except for a reduced PET scan time from 100 to 60 min (Figure 2) and the 
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[
68
Ga]Ga-DOTA-K-A9 being prepared by the optimised method (Section 2.3.2). The mice (n 
= 12) received an intravenous injection of 7.3 ± 2.9 MBq [
68
Ga]Ga-DOTA-K-A9 (300 µl) 




(<70 µl).  
Anatomical localisation was performed by T2 weighted MRI sequence (matrix size 200x192, 
field-of-view 80 mm, 1.0 mm slice thickness, 25 slices, slice gap 0.1 mm, TR/TE 
4999/80 ms; NEX 2). All PET scans were corrected for randoms and reconstructed using a 
3D-OSEM iterative reconstruction algorithm (Tera-Tomo 3D; 4 iterations, 6 subsets; voxel 
size 0.4x0.4x0.4 mm). No correction was made for attenuation and scatter.  
The PET scans were evaluated by a nuclear physician. Sites of infection or inflammation 
were located on the PET images, and the anatomical location in the subcutis was verified on 
the MRI images. The uptake values of the four hottest voxels on five consecutive images 
slices were averaged. Two different reference regions were defined (>20 voxels) in the 
contra-lateral SC region and shoulder muscle (musculus acromiotrapezius), respectively. 
Finally, two lesion-to-background ratios were calculated by dividing the average uptake in 
the infection/inflammation locus by the average uptake in the reference regions. 
 
2.4.4 Post-mortem microbiology and histopathology analyses 
Abscesses from the scanned mice (Table 2) were aseptically excised in toto and collected 
individually in Precellys MK28 tubes from Bertin Technologies (Saint Quentin, France) 
containing ceramic beads. The tubes with abscesses were stored for 1 h at 2 °C before the 
addition of sterile phosphate buffered saline (PBS) (500 µl, 5 °C) and immediate transfer to a 
bead beater (Precellys 24 tissue homogeniser, Bertin Technologies). Homogenisation of the 
abscess was achieved by running a sequence of 5000 rpm in 2x 20 sec, followed by 10 min 
storage at 2 °C and repetition of the sequence. This yielded fully homogenised liquid abscess 
samples from which serial 10-fold dilutions in sterile PBS were performed in triplicates. Each 
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dilution (10 µl) was seeded on 5% blood agar plates from SSI Diagnostic (Hillerød, 
Denmark) and incubated for 24 h at 37 °C before counting CFU. 
To characterise the models histologically, tissue representing the SC lesions was removed 
from selected mice as shown in Table 2. Tissue samples were fixed in 3.7% neutral buffered 
formaldehyde for several days, dehydrated, embedded in paraffin wax, cut in 3 µm thick 
sections, mounted on glass slides, stained with haematoxylin and eosin, and cover slipped 




2.5 In vitro evaluation  
2.5.1 Bacteria preparation 
Sample tubes containing overnight cultures of S. aureus, S. epidermidis, and S. agalactiae, as 
well as CyMol® fixated aliquots of the same bacteria, were pelleted by centrifugation and re-
suspended in 3% skimmed milk powder in phosphate buffered saline (MPBS) and incubated 
for 15 min on ice. This procedure was repeated twice for pre-blocking to reduce subsequent 
non-specific binding of TAMRA-K-A9 to the cells. Each of the cell samples were split in two 
vials: fluorescence sample and control sample, and pelleted by centrifugation.  
 
2.5.2 Morphological binding study 
Table 3 shows the experimental setup for the in vitro binding evaluation of the custom 
synthesised TAMRA-K-A9, which was performed after the mice pilot infection study of 
[
68
Ga]Ga-DOTA-K-A9, to further characterise the bacterial binding of the A9 peptide.  
100 µg (53 nmol) of TAMRA-K-A9 was dissolved in 3% MPBS (1 ml) and the cells in the 
fluorescence sample vials were re-suspended in this 0.05 mM TAMRA-K-A9 solution 
(100 µl), while the cells in the control sample vials were re-suspended in 3% MPBS (100 µl). 
All vials were incubated in the dark for 1 h at room temperature. The cells were subsequently 
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washed once in 0.1% Tween-20 in PBS and twice in PBS and stored on ice until microscopy. 
The membrane-impermeable DNA-binding stain, TOTO®-1, was added to selected vials in a 
working concentration of 0.001 mM (Table 3). This was performed to identify if TAMRA-K-
A9 preferentially bound to (dead) cells with a permeable membrane, indicating an 
intracellular target. All samples were visualised on a Zeiss Axiovert 200 M epifluorescence 
microscope (Göttingen, Germany), using a filter set 43 for TAMRA-K-A9 and filter set 10 
for TOTO®-1. 
 
3 Results and discussion 
3.1 Radiochemistry 
The initial gallium-68 labelling method (Section 2.3.1) yielded 928 ± 70 MBq [
68
Ga]Ga-
DOTA-K-A9 in >91% radiochemical purity with a molar activity of 27 ± 2.0 GBq/µmol at 
end of synthesis, and a stability of 2 h in the product formulation (pH 3.9 - 4.1). In this 
method, the HEPES is necessary in the product formulation where it acts as radical 
scavenger
22,23
 to prevent radiolysis of the radio-peptide. In a previous evaluation of the A9 
68
Ga-labelling, the use of HEPES aq. solutions lower than 0.1 M, resulted in a slightly 
improved radiochemical purity, potentially due to reduced [
68
Ga]Ga-HEPES complexation, 
while the stability of [
68




The acetone content in the formulation when applying the initial gallium-68 labelling method 
necessitated extensive dilution prior to the in vivo injection, thus limiting the radioactivity 
dose given to the mice in the pilot study. Consequently, an optimised preparation method 
omitting the use of acetone was developed (Section 2.3.2), yielding 371 ± 51 MBq [
68
Ga]Ga-
DOTA-K-A9 in 93 ± 0.9% radiochemical purity with a molar activity of 10 ± 1.4 GBq/µmol at 
end of synthesis and a stability up to 2 h in the product formulation (pH 5.1-5.7) (Table 4). 
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Compared to the initial method, the lower yield and thus molar activity of the optimised 
method is partly due to a lower starting activity of [
68
Ga]GaCl3 applied, but also a 
consequence of radioactivity lost during the product purification step.    
As we have reported for another dodecapeptide [
68
Ga]Ga-DOTA-KGSG-A11, the change of 
the eluent from the HCl/acetone solution to the hypertonic NaCl/HCl solution in the pre-
purification of the gallium-68 eluate resulted in an increase in secondary silanol interaction 
between the cationic peptide [
68
Ga]Ga-DOTA-K-A9 and the C18 purification cartridge. This 
phenomenon was further investigated through additional purification experiments with 
[
68
Ga]Ga-DOTA-K-A9, applying different solutions for the pre-conditioning and elution of 
the C18 cartridges (Table 5).  
As seen in the first line of Table 5, when employing the traditional purification setup: C18 
cartridge pre-conditioning with first a 50% EtOH aq. solution then isotonic saline; product 
rinse by isotonic saline; and final a product elution with first a 50% EtOH aq. solution 
followed by isotonic saline for formulation, half of the radioactivity remained on the C18-
cartridge, including retained [
68
Ga]Ga-DOTA-K-A9. During the investigation of the similar 
issue with [
68
Ga]Ga-DOTA-KGSG-A11 on the C18 cartridge, we observed no improvement 
in the elution of the radio-peptide when increasing the ethanol concentration in the product 
elution step.
18
 However, the [
68
Ga]Ga-DOTA-KGSG-A11 peptide was most efficiently eluted 
when using a 50% EtOH/PBS (2%) solution as eluent and the radio-peptide was subsequently 
stable in that formulation up to 2 h. Therefore, when evaluating the [
68
Ga]Ga-DOTA-K-A9 
purification we also tried a few different setups with both a 50% EtOH/PBS (2%) solution pH 
6.5 and a 50% EtOH/0.1 M HEPES aq. solution pH 6.5 as the eluents (Table 5), which 
likewise resulted in an efficient elution [
68
Ga]Ga-DOTA-K-A9 in the activity rage of 514 ± 
93 MBq. Nevertheless, unlike the [
68
Ga]Ga-DOTA-KGSG-A11 peptide, the [
68
Ga]Ga-
DOTA-K-A9 peptide was not stable in formulations of PBS pH 6.5.
18
 And additionally the 
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[
68
Ga]Ga-DOTA-K-A9 also appeared to be less stable in the HEPES/ethanol formulations 
(pH 5.3-6.5) with the radiochemical purity decreasing from around 94% to 80% after 2 hours.  
A possible explanation for this difference in stability of the two compounds is most likely 
found in the peptide sequences and not necessarily a consequence of radiolysis; the activity 
range (514 ± 93 MBq) of the product in the HEPES/ethanol formulations (pH 5.3 - 6.5) was 
lower than the product activity range (928 ± 70 MBq) in the initial 
68
Ga-labelling method 
with the 0.1 M HEPES aq. formulation (pH 3.9 - 4.1). When comparing the peptides A9 
(TDGRRYSSGAMR) and A11 (DVGRRFSSASTR) they have a 50% identical amino acid 
sequence with a few additional positions with small difference between the residues e.g. 
phenylalanine and tyrosine. Despite the similarities, the A9-K-DOTA peptide contains an 
aspartic acid residue placed next to a glycine, as well as a methionine residue, thereby 
making it more susceptible to both hydrolysis and oxidation influenced by pH. However, 
only a few experiments was performed employing HEPES/ethanol in the product formulation 
and the issue was not further investigated, since the aim of the study was the in vivo 
evaluation of [
68
Ga]Ga-DOTA-K-A9. Consequently, an intermediate solution with a 
purification method applying a 0.1 M HEPES aq. solution pH 5.2 for both the C18 cartridge 
pre-conditioning and product rinse, and a 50% EtOH aq. solution as the cartridge eluent was 




3.2 In vivo evaluation 
3.2.1 Model characterisation 
The murine SC S. aureus infection model with µPET/MRI analysis 24 h post-inoculation was 
chosen to obtain an acute inflammatory response with incipient abscess formation, containing 
both dead and viable bacteria.
16,22
 The inflammation model was added to evaluate if the 
imaging agent was able to distinguish between host tissue inflammatory lesions and bacterial 
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infection. Of the two methods typically utilised for creating an inflammation model i.e. 
injection of heat killed bacteria
23-25
 or turpentine oil,
26-28
 the latter method was chosen to gain 
supplement information about tracer accumulation in sterile inflammatory lesions absent of 
bacteria or bacterial components. The same post-inoculation time was applied for the 
turpentine induced inflammation in mice to align the inflammatory responses of the sterile 
and infectious tissue lesions.  
To compare the two lesion types, histopathology and microbiology analyses were performed 
post-mortem (Table 2). Biopsies from 6 turpentine and 3 S. aureus inoculated mice were 
examined histologically. Various tissue elements, e.g. fatty tissue (white and occasionally 
brown), sweat glands, striated muscle fibres, lymph nodes, and occasionally skin (epidermis 
and dermis), were present, often in irregular arrangement, due to multi-purpose use of 
biopsies (Table 2). All biopsies showed presence of acute haemorrhage, and expressed 
similar inflammatory changes. These consisted of areas of oedema (occasionally containing 
fibroblast- or macrophage-like cells, and degranulated mast cells), and areas of accumulated 
neutrophils related to fatty tissue or striated muscle fibres, often being necrotic. In addition, 
two of the S. aureus injected mice (No. 16 and 17) had microcolonies of coccoid bacteria 
located central in necrotic tissue, which was marginated by neutrophils (Figure 3). No viable 
bacteria were located in the tissue sample of the S. aureus injected mouse No. 13 in Table 2. 
This was most likely due to the combination of heterogeneous bacterial distribution and 
division of the abscess tissue for both histopathology and microbiology analyses. To avoid 
this potential problem all other tissue samples from the µPET scanned S. aureus infection 
mice solely went to microbiology analysis, while two additional mice (No. 16 and 17) were 
applied to histologically characterise the infection model (Table 2). The microbiological 
analysis confirmed the aseptic environment in the turpentine inflammation model with no 
CFU grown from the lesions, while in the S. aureus infection model all animals had a clinical 
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distinct abscess formation and all but one of the abscesses contained viable bacteria with an 
average bacterial load of 6.1 ± 1.1 log CFU (Table 2).  
 
3.2.2 Excretion  
In the previously reported in vitro and in vivo studies, [
68
Ga]Ga-DOTA-K-A9 showed a 
preserved binding towards S. aureus after gallium-68 labelling and desirable biodistribution 
features, although it showed a relatively fast metabolic degradation in vivo; with 40% of the 





In this study the µPET scans of the mice, no physiological accumulation of [
68
Ga]Ga-DOTA-
K-A9 was observed in gastrointestinal system, including biliary duct, gall bladder, or 
intestine. Thus, the radiolabelled peptide seemed to be solely excreted by the urinary system. 




no physiological accumulation was seen in the 
bowel and heart. Table 6 shows the radioactivity distribution in the urinary system based on 
the time-activity curves generated from the dynamic [
68
Ga]Ga-DOTA-K-A9 µPET scan 
(Figure 4). The accumulation in the kidneys peaked after 2.5 min with 8.1% ± 0.7% of the 
injected dose located in one kidney after which the activity decreases. Excretion to the urine 
was fast with 55.9% ± 4.1% of the whole body activity being in the urinary bladder 15 min 
post-injection. After 60 min 84.5% ± 1.2% of the activity on the PET image was found in the 
urinary bladder, with the remaining accumulation primarily being located in the kidneys and 
the infectious and inflammatory foci.  
 
3.2.3 Infection and inflammation binding study 







(n = 15) with SC infection are shown in Table 2. In the infection mice of the pilot study (n = 









with the target to background ratios being 1.89 ± 0.88 and 4.24 ± 2.36, 
respectively. Figure 5 illustrates the µPET/MRI scans at 60 - 90 min, in which the [
68
Ga]Ga-
DOTA-K-A9 was primarily localised in the infected abscess and the urinary bladder. The 






doses, 3.2 ± 
1.5 MBq and 11.7 ± 7.3 MBq, respectively, was a consequence of high acetone content in the 
[
68
Ga]Ga-DOTA-K-A9 product formulation, when employing the initial gallium-68 labelling 
method (Section 2.3.1), necessitating an additional pre-injection saline dilution. In the case of 
one mouse, the injected dose of 1.5 MBq yielded too poor image quality to allow proper data 
analysis.  
After the µPET scans of the mice in the pilot infection study confirmed an in vivo 
accumulation of [
68
Ga]Ga-DOTA-K-A9 in the infected foci despite a fast renal clearance, the 
study was expanded with additional 12 mice to investigate the ability of the tracer to 
distinguish sterile inflammation from infection. The synthesis of [
68
Ga]Ga-DOTA-K-A9 was 
optimised, as described in Section 2.3.2, and the scan protocol was additionally adjusted by 
reducing the µPET scan time from 100 min to 60 min according to Figure 2 enabling the 
evaluation of 4 mice on one day. The mice (n = 12) in the infection and inflammation 






in the same range 




given when possible, due to a 60 min post-
injection delay of the [
18
F]FDG scan. The results of the µPET/MRI scans showed that 
[
68
Ga]Ga-DOTA-K-A9 accumulated in both infectious (Figure 6) and sterile inflammatory 
foci (Figure 7), thus not being bacteria-specific. Furthermore, comparing the accumulation in 
lesion and contra-lateral subcutis a higher ratio was found in inflammation compared to 
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seen in brown adipose tissue of some mice, this did not significantly interfere with the image 
analysis.  
The accumulation of [
68
Ga]Ga-DOTA-K-A9 in both sterile inflammation and infection 
indicates that factors of the inflammatory response are involved in the uptake. The cationic 
properties of the A9 peptide could potentially have contributed to the uptake mechanism in 
vivo through electrostatic interactions with negatively charged components of dead bacterial 
cells and damaged necrotic host tissue cells. This binding pattern has previously been 
described in the evaluation of bacterial membrane-binding imaging agents, such as 
ubiquicidin and bis-dipicolylamine-zinc
2,3,29,30
, where cationic domains in the tracers bound 
to negatively charged molecules in the bacterial membrane. In the case of bis-dipicolylamine, 
the binding also included negatively charged structures becoming accessible through bacterial 
cell lysis and/or disruption of plasma membrane in mammalian cells during necrosis. 
However, the lysed material from bacteria and host tissue cells would need to be locally 
present in large excess to avoid blocking by unlabelled A9 peptide.  
  
3.3 In vitro evaluation 
The A9 peptide was originally selected by phage-display towards a S. aureus biofilm, but it 
was not evident to what extent the binding was occurring towards viable or dead bacteria or 





subsequently confirmed to bind to both Gram-positive and negative bacteria in vitro.
18
 That 
previously reported experiment was performed on bacteria grown overnight, but as no 
subsequent microbiological analyses were performed to confirm the viability of the bacteria, 
it was not known if the observed binding necessitated living bacteria. To clarify this, the 
binding of the fluorescence analogue TAMRA-K-A9 was evaluated in vitro towards 
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S. aureus and two other bacterial strains often associated with prosthesis related infections 
(Table 3) to investigate if the accumulation observed in the murine infections was selective to 
viable or dead bacteria. However, only few cells in fresh cultures bound the probe (Figure 
8A, 8D, and 8G). This led us to hypothesise that the target was intracellular and therefore 
only accessible in cells with a compromised membrane. The membrane-impermeable DNA 
stain TOTO®-1 was therefore combined with TAMRA-K-A9 to assess membrane integrity, 
and we confirmed that TAMRA-K-A9 only bound to cells with a compromised membrane 
(Figure 8C, 8F). To further corroborate this conclusion, we evaluated the binding of 
TAMRA-K-A9 in samples of dead bacteria and confirmed that nearly all bacteria in these 
samples bound the probe (Figure 8B, 8E, and 8H). Additionally, the binding was not confined 
to S. aureus but occurred with all the bacterial species tested (Table 3). Altogether, the results 
indicated that TAMRA-K-A9 binds to an intracellular epitope in dead bacteria with 
permeable membranes, and that the epitope were present in all bacterial species tested. 
Although, both [
68
Ga]Ga-DOTA-K-A9 (Figure 1A) and TAMRA-K-A9 (Figure 1B) are 
based on the same binding pharmacophore, i.e. the A9 peptide, it cannot be completely 
disregarded that the individual imaging moiety could somehow influence their affinity 
differently. However, as the A9 peptide was initially selected towards a S. aureus biofilm, i.e. 
aggregated viable and dead bacteria embedded in self-produced matrix, the identified affinity 
of the peptide towards an intracellular epitope in dead bacteria is explicable.  
 
4 Conclusion  
The in vivo study did not show selectivity of [
68
Ga]Ga-DOTA-K-A9 towards infection, as the 
tracer accumulated in mice with both infection and turpentine induced inflammation and it is 
therefore not applicable as a bacteria-specific imaging agent. However, The [
68
Ga]Ga-
DOTA-K-A9 tracer was able to detect low levels of inflammation with limited background 
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uptake on the same level as [
18
F]FDG. The lesion localisation of [
68
Ga]Ga-DOTA-K-A9 in 
the murine sterile inflammation model prove that the accumulation of the imaging agent 
occurs due to factors associated with the inflammatory response, which may include 
increased blood flow, membrane permeability, as well as the host inflammatory cells. And 
since the previous in vitro results showed binding of [
68
Ga]Ga-DOTA-K-A9 towards S. 
aureus,
18
 while the present study identified a binding of the fluorescence analogue TAMRA-
K-A9 to an intracellular epitope in dead bacteria with permeable membranes. The uptake is 
presumably a combination of local hyperaemia, vascular leakiness and/or binding to an 
epitope present in dead bacteria and inflammatory cells potentially by electrostatic 
interactions of the cationic A9 peptide.  
In the continued search of potential infection-specific PET tracers we still regard the selection 
process by phage-display as a valuable tool to identify peptides with a selective binding 
affinity to bacterial components.  
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Table 1: Bacteria applied in the evaluation of the [68Ga]Ga-DOTA-K-A9 and TAMRA-K-A9 peptides 
ID Species Reference No. Source Application 
S. aureus (130858) Staphylococcus 
aureus 
2011-130858 Human synovial fluid
a
  Murine SC infection 
In vitro binding study 
S. epidermidis Staphylococcus 
epidermidis 
DSM 1798 Culture collection In vitro binding study 
S. agalactiae Streptococcus 
agalactiae 
NCTC 11078 Culture collection In vitro binding study 
All bacteria were stored at -80 °C. DSM: Deutsche Sammlung von Mikroorganismen, Braunschweig, Germany. NCTC: 
National Collection of Type Cultures, Salisbury, UK. a) Knee prosthesis patient at the Department of Clinical Microbiology, 
Aalborg University Hospital, Denmark.   
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Target/background ratios on µPET   Post-mortem analyses 














1 Infection ≥24 4.3 19.9 ≥5 1.91 6.90 n/a n/a 6.6 n/a 
2 Infection ≥24 1.5  6.2 ≥5 1.00 a 3.40 n/a n/a 6.8 n/a 
3 Infection ≥24 3.8 8.9 ≥5 2.75 2.42 n/a n/a 6.4 n/a 
Mean ± SD  3.2 ± 1.5 11.7 ±7.3  1.89 ± 0.88 4.24 ± 2.36   6.6 ± 0.2  
4 Inflammation 25.0 11.5 18.9 6.25 3.31 3.31 4.24 5.22 0.0 Yes 
5 Inflammation 26.6 3.6 b 4.6 6.05 3.31 3.53 2.86 4.28 0.0 Yes 
6 Inflammation 29.7 8.6 9.4 n/a g 3.80 n/a g 4.40 n/a g 0.0 Yes 
7 Inflammation 25.1 9.5 7.6 5.88 n/a f 1.00  n/a f 1.00  0.0 Yes 
8 Inflammation 26.5 4.1 12.2 5.92 2.43 1.00  3.85 1.00  0.0 Yes 
9 Inflammation 28.0 10.4 9.0 5.70 5.37 2.91 c 4.67 1.66 c 0.0 Yes 
Mean ± SD 26.8 ± 1.8 8.0 ± 3.3 10.3 ± 4.9 358 ± 12 3.64 ± 1.08 2.35 ± 1.25 4.00 ± 0.71 2.63 ± 1.98 0.0 ± 0.0  
10 Infection 29.3 4.3 6.3 5.72 2.15 1.00  2.69 1.00  4.4 n/a e 
11 Infection 24.1 10.2 12.6 9.03 2.20 2.27 c 3.16 2.02 c 0.0 d n/a e 
12 Infection 25.5 4.8 9.7 9.25 2.57 1.00 c 4.49 1.00 c 5.9 n/a e 
13 Infection 28.1 7.7 h n/a n/a n/a n/a n/a n/a 7.1 Yes 
14 Infection 30.0 9.7 b 6.6 n/a g 2.15 n/a g 2.69 n/a g 7.0 n/a e 
15 Infection 31.8 3.7 4.5 4.62 3.16 2.74 c 4.97 2.21 c 6.0 n/a e 
Mean ± SD 28.1 ± 2.9 6.7 ± 2.9 7.9 ± 3.2 429 ± 140 2.45 ± 0.44 1.75 ± 0.69 3.60 ± 1.06 1.56 ± 0.65 6.1 ± 1.1  
16 Infection 
Mice applied for histological characterization of the infection model  
Yes 
17 Infection Yes 
For mice No. 1-3 in the pilot study the µPET scans are summed from 60-90 min, while for mice No. 4-15 the scans are summed from 30-60 min. a) The injected dose of [68Ga]Ga-DOTA-K-A9 
yielded too poor image quality to allow proper data analysis. b) Paravenous injection of the tracer. c) High physiological uptake in brown adipose tissue. d) No bacteria were grown from this 
tissue abscess, thus not included in the mean ± SD calculation. e) Histology was not performed to avoid dividing the abscess. f) Image analysis not possible, due to artefact from retrograde 
leakage of injected tracer. g) The anesthetised mouse died shortly after [18F]FDG injection. h) The anesthetised mouse died during the µPET scan. n/a: not available, either the analyses were not 
performed or the results are not available for various reasons (e-h). 
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Table 3: Experimental setup and results of the in vitro binding evaluation of TAMRA-K-A9 on various bacteria 
Bacteria Sample content Microscopy results Figure 
S. aureus  Viable TAMRA-K-A9 
& added TOTO®-1 
Uptake of TAMRA-K-A9 in very few cells  
The uptake is almost exclusively in dead bacteria  
8A 
8C 
  MPBS No fluorescence  
 Dead  TAMRA-K-A9 Higher uptake of TAMRA-K-A9 compared to S. aureus viable cell test  8B 
 
 MPBS No fluorescence 
 
S. agalactiae Viable TAMRA-K-A9 
& added TOTO®-1 
Uptake of TAMRA-K-A9 in more cells compared to viable S. aureus  
The uptake is only in dead bacteria 
8D 
8F 
  MPBS No fluorescence  
 Dead  TAMRA-K-A9 Higher uptake of TAMRA-K-A9 compared to S. agalactiae viable cell test 8E 
  
MPBS No fluorescence 
 
S. epidermidis Viable TAMRA-K-A9 Uptake of TAMRA-K-A9 in very few cells as seen with S. aureus 8G 
  
MPBS No fluorescence 
 
 Dead  TAMRA-K-A9 Uptake of TAMRA-K-A9 in all the dead bacteria 8H 
  MPBS No fluorescence  
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Table 4: Stability of the [68Ga]Ga-DOTA-K-A9 peptide in product formulations after purification  







TLC EOS 99% ± 0.5% 
HPLC EOS 93% ± 0.8% 
1 h 91% ± 1.0% 
2.5 h 90% ± 0.5% 
EOS: End of synthesis. Results are given as mean ± SD, n ≥ 3. 
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Table 5: Optimisation of [68Ga]DOTA-K-A9 purification on C18-light cartridge 
Purification methods 
N 
% of starting radioactivity  
Radiochemical purity 
Product (%) 
Pre-condition Product rinse Product elution C18 waste C18 cartridge Product 
1. 50% EtOH/H2O 
2. Isotonic saline 
Isotonic saline 
1. 1 ml 50% EtOH/H2O 
2. 5 ml isotonic saline 
5 1.05 ± 0.35 51.3 ± 12.0 33.4 ± 13.1 91.8 ± 0.5 
1. 50% EtOH/PBS pH 6.5 
2. Isotonic saline 
Isotonic saline 
1. 1 ml 50% EtOH/PBS 
 pH 6.5 
2. Isotonic saline 
1 0.60 2.80 84.0 88 
1. 50% EtOH/ 0.1 M 
HEPES pH 6.5 
2. Isotonic saline 
Isotonic saline 
1. 1 ml 50% EtOH/0.1 M 
HEPES pH 6.5 
2. Isotonic saline 
1 0.97 5.97 80.8 94 
1. 50% EtOH/H2O 
2. 0.1 M HEPES pH 6.5 
0.1 M HEPES 
pH 6.5 
1. 1 ml 50% EtOH/H2O 
2. 0.1 M HEPES pH 6.5 
1 0.63 5.86 81.9 94 
Combined for 0.1 M HEPES and PBS at pH 6.5 3 0.73 ± 0.21 4.88 ± 1.80 82.2 ± 1.64 92.0 ± 3.5 
1. 50% EtOH/H2O 
2. 0.1 M HEPES pH 5.2 
0.1 M HEPES 
pH 5.2 
1. 1 ml 50% EtOH/H2O 
2. 0.1 M HEPES pH 5.2 
1 1.03 23.5 58.9 95 
1. 50% EtOH/H2O 
2. 0.1 M HEPES pH 5.2 
0.1 M HEPES 
pH 5.2 
1. 1 ml 50% EtOH/H2O 
2. Isotonic saline 
8 1.40 ± 0.38 28.8 ± 5.04  55.7 ± 3.61 92.9 ± 0.8 
Combined for 0.1 M HEPES at pH 5.2 9 1.36 ± 0.37 28.2 ± 5.03 56.1 ± 3.54 93.1 ± 1.1 
N: number of occurrences. PBS: sodium phosphate (2%) in saline. Radiochemical purity: Measured by radio-HPLC at end of synthesis. Gallium-68 colloid ≤1% measured by radio-TLC. The 
radioactivity is decay corrected.  
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Table 6: Radioactivity distribution in the murine urinary system from time-activity curves during [68Ga]Ga-DOTA-K-A9 
µPET scan 
Time post-injection 
% of the whole body radioactivity 
Left kidney Urinary bladder 
2.5 min 8.06 ± 0.70 18.51 ± 3.84 
5.0 min 2.52 ± 0.30 32.46 ± 4.32 
15 min 3.11 ± 0.21 55.88 ± 4.12 
25 min 2.07 ± 0.07 68.88 ± 3.10 
40 min 1.40 ± 0.12 78.18 ± 2.07 
60 min 0.97 ± 0.12 84.54 ± 1.17 
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Figure 1: Molecular structure of (A) the radiolabelled peptide [68Ga]Ga-DOTA-K-A9 (1937 Da) and (B) the fluorescence 
analogue TAMRA-K-A9 (1896 Da). In the two compounds, the A9 peptide, TDGRRYSSGAMR, are supplied with an 
imaging moiety, [68Ga]Ga-DOTA or TAMRA, respectively, conjugated through an additional lysine residue at the C-
terminal. The C-terminal is not believed to participate in the binding as it was connected to the phage particle in the 
preceding selection experiments. 
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Figure 2: Illustration of the mice scans timeline in the main comparison study. The scan protocol was optimized from the 
pilot study, by reducing the µPET-scan time from 100 to 60 min facilitating up to four consecutive [68Ga]Ga-DOTA-K-A9 
µPET/MRI scans, prior to the following [18F]FDG µPET/MRI scan of each mouse five hours later. In this study setup, four 
mice was evaluated a day.  
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Figure 3: Histopathology of skin lesions in mice approximately 24 hours after inoculation with S. aureus (A and B) or 
injection with turpentine oil (C and D). Area in A and C marked with an asterisk (*) are enlarged and presented as B and D, 
respectively. Essentially the lesions, whether induced by S. aureus (A and B) or turpentine oil (C and D), are identical: 
striated muscle (NS) and adipose tissue (NA) presents with necrosis, and these areas are demarcated and infiltrated with 
neutrophils (NEU); viable striated muscle (VS) and viable adipose tissue is located peripheral to the necrotic centers. A 
bacterial colony (S. aureus) is present in the mouse inoculated with S. aureus. Haematoxylin and eosin staining. Bars: 160 
µm (A and C), 40 µm (B), and 25 µm (D). 
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Figure 4: Distribution of radioactivity within the field of view during µPET scan of [68Ga]DOTA-K-A9 as percentage of the 
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Figure 5: µPET/MRI scans of mouse No. 3 with subcutaneous S. aureus infection. Images of [18F]FDG (8.9 MBq) in coronal 
plane dorsal view (A) and transversal plane caudal view (B). Images of [68Ga]Ga-DOTA-K-A9 (3.8 MBq) in coronal plane 
dorsal view (C) and transversal plane caudal view (D). All images are summed from 60 - 90 min. The red arrows indicate the 
infectious focus with accumulation of both tracers. Additional, [68Ga]Ga-DOTA-K-A9 showed a low background binding 
with most of the radioactivity being in the urinary bladder.   
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Figure 6: µPET/MRI scans of mouse No. 12 with subcutaneous S. aureus infection. Images of [18F]FDG (9.7 MBq) in 
coronal plane ventral view (A) and transversal plane caudal view (B). Images of [68Ga]Ga-DOTA-K-A9 (4.8 MBq) in 
coronal plane ventral view (C) and transversal plane caudal view (D). All images are summed from 30 - 60 min. The red 
arrows indicate the infectious focus exclusively with accumulation [68Ga]Ga-DOTA-K-A9, while the yellow arrow 
illustrates [18F]FDG accumulation in brown adipose tissue. 
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Figure 7: µPET/MRI scans of mouse No. 4 with subcutaneous turpentine induced inflammation. Images of [18F]FDG (18.9 
MBq) in coronal plane ventral view (A) and transversal plane caudal view (B). Images of [68Ga]Ga-DOTA-K-A9 (11.5 
MBq) in coronal plane ventral view (C) and transversal plane caudal view (D). All images are summed from 30 - 60 min. 
The red arrows indicate the inflammatory foci with a similar accumulation pattern of both tracers.  
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Figure 8: Epifluorescence imaging of TAMRA-K-A9 (red) binding to S. aureus (A-C), S. agalactiae (D-F) and S. 
epidermidis (G-H). The peptide probe only bound to few cells if the cells were prepared fresh (A+D+G), whereas all cells 
appeared to bind the probe if they had been killed and fixed (B+E+H). To verify if only cells with a damaged membrane 
would bind the peptide probe, we combined peptide labelling with the membrane-impermeable DNA stain TOTO®-1 
(green) (C+F). Cells binding both TOTO®-1 and the peptide probe appear yellow-orange, and the images confirm that only 
cells with a damaged membrane would bind the peptide probe, which indicates an intracellular epitope. 
 
